Format

Send to

Choose Destination
J Cell Biol. 2019 May 15. pii: jcb.201902048. doi: 10.1083/jcb.201902048. [Epub ahead of print]

The PHLPP2 phosphatase is a druggable driver of prostate cancer progression.

Author information

1
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY dgn2001@med.cornell.edu.
2
Division of Hematology and Medical Oncology, Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, NY.
3
Department of Pharmacology, University of California San Diego, La Jolla, CA.
4
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
5
Department of Pathology, University of Michigan, Ann Arbor, MI.
6
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY trotman@cshl.edu.

Abstract

Metastatic prostate cancer commonly presents with targeted, bi-allelic mutations of the PTEN and TP53 tumor suppressor genes. In contrast, however, most candidate tumor suppressors are part of large recurrent hemizygous deletions, such as the common chromosome 16q deletion, which involves the AKT-suppressing phosphatase PHLPP2. Using RapidCaP, a genetically engineered mouse model of Pten/Trp53 mutant metastatic prostate cancer, we found that complete loss of Phlpp2 paradoxically blocks prostate tumor growth and disease progression. Surprisingly, we find that Phlpp2 is essential for supporting Myc, a key driver of lethal prostate cancer. Phlpp2 dephosphorylates threonine-58 of Myc, which renders it a limiting positive regulator of Myc stability. Furthermore, we show that small-molecule inhibitors of PHLPP2 can suppress MYC and kill PTEN mutant cells. Our findings reveal that the frequent hemizygous deletions on chromosome 16q present a druggable vulnerability for targeting MYC protein through PHLPP2 phosphatase inhibitors.

PMID:
31092557
DOI:
10.1083/jcb.201902048

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center